• Loading stock data…

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Last Updated on March 4, 2022 by GlobeNewsWire

COPENHAGEN, Denmark, March 4, 2022 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

1.Details of the person discharging managerial responsibilities/person closely associated a)NamePaul Chaplin2.Reason for the notificationa)Position/statusPresident and Chief Executive Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument

Identification code

Restricted Stock Units

DK0015998017

b)Nature of the transactionGrantc)Price(s) and volume(s)Price(s)Volume(s) DKK 108.7112,543d)Aggregated information Aggregated volumePrice

12,543
DKK 1,363,566.00

e)Date of the transaction2022-03-04f)Place of the transactionOutside a trading venue

1.Details of the person discharging managerial responsibilities/person closely associated a)NameHenrik Juuel2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Financial Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument

Identification code

Restricted Stock Units

DK0015998017

b)Nature of the transactionGrantc)Price(s) and volume(s)Price(s)Volume(s) DKK 108.716,480d)Aggregated information Aggregated volumePrice

6,480
DKK 704,425.00

e)Date of the transaction2022-03-04f)Place of the transactionOutside a trading venue1.Details of the person discharging managerial responsibilities/person closely associated a)NameJean-Christophe May2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Commercial Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument

Identification code

Restricted Stock Units

DK0015998017

b)Nature of the transactionGrantc)Price(s) and volume(s)Price(s)Volume(s) DKK 108.734,726d)Aggregated information Aggregated volumePrice

4,726
DKK 513,839.00

e)Date of the transaction2022-03-04f)Place of the transactionOutside a trading venue1.Details of the person discharging managerial responsibilities/person closely associated a)NameLaurence De Moerlooze2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Medical Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument

Identification code

Restricted Stock Units

DK0015998017

b)Nature of the transactionGrantc)Price(s) and volume(s)Price(s)Volume(s) DKK 108.715,754d)Aggregated information Aggregated volumePrice

5,754
DKK 625,516.00

e)Date of the transaction2022-03-04f)Place of the transactionOutside a trading venue1.Details of the person discharging managerial responsibilities/person closely associated a)NameAnu Helena Kerns2.Reason for the notificationa)Position/statusExecutive Vice President and Chief People Officer of Bavarian Nordic A/Sb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameBavarian Nordic A/Sb)LEI2138006JCDVYIN6INP514.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducteda)Description of the financial instrument, type of instrument

Identification code

Restricted Stock Units

DK0015998017

b)Nature of the transactionGrantc)Price(s) and volume(s)Price(s)Volume(s) DKK 108.714,363d)Aggregated information Aggregated volumePrice

4,363
DKK 474,300.00

e)Date of the transaction2022-03-04f)Place of the transactionOutside a trading venue

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN(R), we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Contacts
Europe: Rolf Sass Sorensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 04 / 2022

Attachment

2022-04-en




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: